BIOA BioAge Labs Inc.

Price (delayed)

$17.115

Market cap

$760.81M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.4

Enterprise value

$523.07M

?
Relative Growth: Rel. Growth: 23
Relative Strength: Rel. Strength: 94
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 29

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets ...

Highlights
BIOA's quick ratio has surged by 79% year-on-year and by 73% since the previous quarter
BIOA's debt has dropped by 61% year-on-year and by 27% since the previous quarter
BIOA's net income is down by 27% year-on-year and by 12% since the previous quarter
BIOA's EPS is down by 7% since the previous quarter

Key stats

What are the main financial stats of BIOA

BIOA stock price

How has the BioAge Labs stock price performed over time
Intraday
6.7%
1 week
0.38%
1 month
2.98%
1 year
300.82%
YTD
29.37%
QTD
-2.14%

Financial performance

How have BioAge Labs's revenue and profit performed over time
Revenue
$10.32M
Gross profit
$10.32M
Operating income
-$101.71M
Net income
-$89.93M
Gross margin
100%
Net margin
-871.8%
The operating margin has soared by 83% YoY and by 4.4% from the previous quarter
BIOA's net margin has surged by 82% year-on-year and by 2.7% since the previous quarter
BIOA's net income is down by 27% year-on-year and by 12% since the previous quarter
BIOA's operating income is down by 24% year-on-year and by 10% since the previous quarter

Price vs fundamentals

How does BIOA's price correlate with its fundamentals

Growth

What is BioAge Labs's growth rate over time

Valuation

What is BioAge Labs stock price valuation
P/E
N/A
P/B
2
P/S
70.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
50.7
BIOA's EPS is down by 7% since the previous quarter
The P/B is 45% more than the last 4 quarters average of 1.3
The company's equity rose by 39% QoQ and by 21% YoY
The stock's price to sales (P/S) is 33% more than its last 4 quarters average of 49.7
The revenue has increased by 15% QoQ

Efficiency

How efficient is BioAge Labs business performance
BIOA's return on sales has surged by 82% year-on-year and by 2.4% since the previous quarter
The ROIC has soared by 82% YoY and by 8% from the previous quarter
BIOA's ROE is up by 22% year-on-year but it is down by 5% since the previous quarter
BIOA's ROA is down by 16% year-on-year and by 7% since the previous quarter

Dividends

What is BIOA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIOA.

Financial health

How did BioAge Labs financials performed over time
BIOA's current ratio has soared by 81% year-on-year and by 74% since the previous quarter
BIOA's quick ratio has surged by 79% year-on-year and by 73% since the previous quarter
BIOA's debt is 99% smaller than its equity
The debt to equity has dropped by 67% year-on-year and by 50% since the previous quarter
BIOA's debt has dropped by 61% year-on-year and by 27% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.